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Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a
interaction in the hypothalamic neurons of mice
Abstract
Second generation antipsychotics, particularly olanzapine, induce severe obesity, which is associated with
their antagonistic effect on the histamine H1 receptor (H1R). We have previously demonstrated that oral
administration of olanzapine increases the concentration of neuropeptide Y (NPY) in the hypothalamus of
rats, accompanied by hyperphagia and weight gain. However, it is unclear if the increased NPY after
olanzapine administration is due to its direct effect on hypothalamic neurons and its H1R antagonistic
property. In the present study, we showed that with an inverted U-shape dose-response curve, olanzapine
increased NPY expression in the NPY-GFP hypothalamic neurons; however, this was not the case in the
hypothalamic neurons of H1R knockout mice. Olanzapine inhibited the interaction of H1R and GHSR1a
(ghrelin receptor) in the primary mouse hypothalamic neurons and NPY-GFP neurons examined by
confocal fluorescence resonance energy transfer (FRET) technology. Furthermore, an H1R agonist, FMPH
inhibited olanzapine activation of GHSR1a downstream signaling pAMPK and transcription factors of NPY
(pFOXO1 and pCREB) in the hypothalamic NPY-GFP cell. However, an olanzapine analogue (E-Olan) with
lower affinity to H1R presented negligible enhancement of pCREB within the nucleus of NPY neurons.
These findings suggest that the H1R antagonist property of olanzapine inhibits the interaction of H1R and
GHSR1a, activates GHSR1a downstream signaling pAMPK-FOXO1/pCREB and increases hypothalamic
NPY: this could be one of the important molecular mechanisms of H1R antagonism of olanzapineinduced obesity in antipsychotic management of psychiatric disorders.
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Abstract
Second generation antipsychotics, particularly olanzapine, induce severe obesity, which is
associated with their antagonistic effect on the histamine H1 receptor (H1R). We have previously
demonstrated that oral administration of olanzapine increases the concentration of neuropeptide Y
(NPY) in the hypothalamus of rats, accompanied by hyperphagia and weight gain. However, it is
unclear if the increased NPY after olanzapine administration is due to its direct effect on
hypothalamic neurons and its H1R antagonistic property. In the present study, we showed that
with an inverted U-shape dose-response curve, olanzapine increased NPY expression in the NPYGFP hypothalamic neurons; however this was not the case in the hypothalamic neurons of H1R
knockout mice. Olanzapine inhibited the interaction of H1R to GHSR1a (ghrelin receptor) in the
primary mouse hypothalamic neurons and NPY-GFP neurons examined by confocal fluorescence
resonance energy transfer (FRET) technology. Furthermore, an H1R agonist, FMPH inhibited
olanzapine activation of GHSR1a downstream signaling pAMPK-UCP2 and transcription factors
of NPY (pFOXO1 and pCREB) in the hypothalamic NPY-GFP cell. However, an olanzapine
analogue (OlzEt) with lower affinity to H1R presented negligible enhancement of pCREB within
the nucleus of NPY neurons. These findings suggest that the H1R antagonist property of
olanzapine inhibits the interaction of H1R to GHSR1a, activates GHSR1a downstream signaling
pAMPK-UCP2-FOXO1/pCREB and increases hypothalamic NPY, which could be one of
important molecular mechanism of H1R antagonism of olanzapine-induced obesity in
antipsychotic management of psychiatric disorders.
Key words: antipsychotic drug, histamine H1 receptor, neuropeptide Y, hypothalamus, ghrelin
receptor 1a, weight gain, BMI
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Introduction
Second generation antipsychotic drugs (SGAs) are widely prescribed for a growing number of
mental illnesses including schizophrenia, bipolar disorder, dementia, major depression, autism,
and Tourette’s disease [1]. SGAs can cause serious side effects including body weight gain, obesity
and metabolic syndrome, leading to further chronic life-threatening diseases and medication noncompliance [2; 3]. Olanzapine has one of the highest obesogenic liabilities of all SGAs [4; 5], with
a significant body of evidence demonstrating its association with metabolic hormone imbalance,
hyperphagia, and adiposity [6; 7; 8]. Despite a vast body of literature examining antipsychotic
metabolic side-effects, the molecular mechanism underlying SGA-induced obesity is still largely
unclear.
Neuropeptide Y (NPY) is an orexigenic neuropeptide in the hypothalamus and plays an important
role in regulating positive energy balance. Previously, we found that oral administration of
olanzapine increased NPY level in the hypothalamus of rats with hyperphagia and weight gain [9].
However, it is unclear if the activation of NPY induced by olanzapine is due to its direct effect on
hypothalamic neurons or a secondary effect of obesity. Therefore, the precise mechanism of
olanzapine induced NPY should be investigated at cellular level. In the hypothalamic arcuate
nucleus (Arc), more than 90% NPY neurons express the growth hormone secretagogue receptor
1a (GHSR1a; also called the ‘ghrelin receptor’) [10]. GHSR1a promotes mitochondrial βoxidation through AMP-activated protein kinase (AMPK) phosphorylation and subsequent
activity of carnitine palmitoyl transferase 1 (CPT1), which transports fatty acids into the
mitochondria, and uncoupling protein-2 (UCP2) [11; 12]. GHSR1a-induced activation of the
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AMPK-CPT1-UCP2 pathway increases NPY mRNA expression by modulating intracellular
transcriptional factors, forkhead box O1 (FOXO1) and the phosphorylated cAMP-response
element-binding protein (pCREB), which are translocated to the nucleus to initiate NPY promoter
activity [13; 14; 15; 16]. Therefore, GHSR1a-AMPK- FOXO1/p-CREB play important role in
activation of NPY in the hypothalamus.
Olanzapine’s obesogenic effect is linked to its antagonistic effect on the histamine H1 receptors.
It is reported that H1R antagonism of the antipsychotics activates hypothalamic AMP-kinase to
increase food intake and induce weight gain [17; 18; 19]. H1R mRNA is expressed in the Arc [20]
where GHSR1a is highly expressed. Accumulating data over the last few years have shown that
the GHS-R1a can form a dimer with G-protein coupled receptors involved in appetite signaling
and reward, including the GHS-R1b, the melanocortin 3 (MC3), dopamine (D1 and D2), and
serotonin 2C (5-HT2C) receptors [21]. Both H1R and GHSR1a regulate AMPK and are colocalized in the hypothalamic neurons, H1R and GHSR1a may interact and regulate AMPK
signaling in the hypothalamus, responsible for olanzapine’s H1R antagonism effect on activation
of AMPK and its downstream NPY for positive energy balance.
In the present study, we examined the H1R antagonism of olanzapine in regulation of NPY in the
hypothalamic neurons by using cultured primary hypothalamic neurons, NPY-GFP cell line and
hypothalamic A59-NPY neurons. Furthermore, interaction of H1R and GHSR1a in hypothalamic
neurons was investigated by confocal fluorescence resonance energy transfer (FRET) technology,
as well as the effects of olanzapine on the interaction and GHSR1a signaling pathways (AMPKFOXO1/p-CREB) were also examined.
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Results
Olanzapine increased NPY expression in NPY-GFP cell line associated with H1R property.
NPY is one of the most important neurotransmitters stimulating positive energy balance and
promoting weight gain [22]. We have previously shown that olanzapine increases hypothalamic
NPY of rats with hyperphagia and weight gain [23]. To further testify whether or not olanzapine
can directly increase NPY in the hypothalamic neurons, we measured the dosage effects of
olanzapine in NPY-GFP cells. We observed an inverted U-shape dose-response effect, where
olanzapine increased NPY (Fig 1A). Olanzapine at 10 and 25µM increased NPY concentrations
with the maximum effect at 25µM, while olanzapine at 1, 50 and 100µM did not significantly
affect NPY concentrations (Fig 1A). Olanzapine’s H1R antagonist property has been reported to
increase NPY in an in vivo study [18]. Here, we examined the effects of pyrilamine (a selective
antagonist of H1R) and FMPH (a selective agonist of H1R) on NPY in NPY-GFP cells. Pyrilamine
increased NPY at 1, 5, and 10µM (Fig 1B), while FMPH (from 0.5-5µM) decreased NPY
concentrations (Fig 1C). These data demonstrated that both olanzapine and the H1R antagonist
increased NPY, but the H1R agonist reduced NPY concentrations in hypothalamic neurons.
Olanzapine does not increase hypothalamic NPY of H1R knockout heterozygous mice.
To

further

investigate

the

H1R

of

olanzapine

regulating

hypothalamic

NPY,

immunocytochemistry-based co-localization of endogenous NPY and H1R was applied in cultured
neonatal hypothalamus neurons of H1R knockout mouse in response to olanzapine. In cultured
primary hypothalamic neurons, hypothalamic neurons from H1R knockout mouse showed
significantly lower H1R levels compared with wildtype mice (Fig 2A and 2B). Olanzapine
significantly increased NPY concentrations in wildtype mice (P<0.01), but not in H1R knockout
5

mice (Fig 2A and 2C). The results suggest that H1R is mechanistically essential for olanzapine
increasing NPY in the hypothalamic neurons.
Olanzapine inhibited the interaction of H1R to GHSR1a in the hypothalamic neurons.
Hypothalamic NPY neurons express both H1R and GHSR1a [24; 25]. GHSR1a is constantly active,
even in an absence of a natural ligand ghrelin. GHSR1a dimerizes with a wide array of receptors
including D2R. Since both H1R and GHSR1a regulate NPY, we examined if there is interaction
between H1R and GHSR1a and if olanzapine can regulate their interaction. First,
immunocytochemistry revealed that mouse postnatal hypothalamic Arc neurons (DIV 10)
endogenously expressed H1R and GHSR1a, which co-localized in NPY neurons (Fig. 3A).
Confocal FRET displayed the heterodimers of H1R and GHSR1a in NPY neurons (Fig 3B). The
control group showed that no FRET was detected without either H1R antibody (acceptor, Fig 3C)
or GHSR1a antibody (donor, Fig 3D) applied in these hypothalamic NPY neurons. Therefore, our
results demonstrated a physical interaction and receptor heterodimer complex formation between
the natively expressed H1R and GHSR1a in hypothalamic NPY neurons. FRET efficiencies
(FRETeff) for the sensitized emission (SE) in response to olanzapine, FMPH, and their
combination were measured. In some neurons, FMPH (5μM) significantly increased FRET
efficiency (p<0.05), while olanzapine (25μM) and PYR (5μM) decreased FRET efficiency (p<0.01
Fig 3E). Similarly, in the dendrite of neurons, FRET efficiency was significantly increased by
FMPH, and decreased by olanzapine and PYR (Fig 3F).
Next, we further confirmed that H1R and GHSR1a were co-localized in NPY-GFP cell line (Fig
4A). Confocal FRET showed that H1R and GHSR1a were able to form heterodimers in the NPYGFP cell (Fig 4B). A combination of FMPH and olanzapine decreased FRET efficiency compared
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with FMPH alone (p<0.01, Fig 4C), suggesting that H1R antagonism of olanzapine blocks H1R
agonist effect of FMPH on interaction between H1R and GHSR1a.

H1R antagonism of olanzapine-activated hypothalamic GHSR1a downstream signaling
molecules in NPY-GFP cells
It is known that GHSR1a activates AMPK and subsequent uncoupling protein-2 UCP2 activity
increment, which is required to support the signal transduction system and ensure efficient
expression of transcription factors (FOXO1 and p-CREB ) of NPY [26; 27; 28]. To understand the
effects of H1R antagonism of olanzapine on the downstream signaling molecules of GHSR1a, the
expression of pAMPK, UCP2, FOXO1, and p-CREB was examined in the hypothalamic NPYGFP cells treated with olanzapine (25μM) with or without addition of FMPH (5μM ) using Western
blots. The levels of pAMPK, FOXO1 and pCREB were significantly increased by olanzapine
compared with controls (p<0.05, Fig 5A, C and D). The UCP-2 concentration had a trend of
increase in olanzapine group compared with control group, but did not reach statistical significance
(Fig 5B). FMPH significantly reversed the olanzapine-induced increment of GHSR1a downstream
signaling molecules (p<0.05, Fig 5 A-D). The results suggested that H1R antagonist of olanzapine
might activate GHSR1a and its downstream signaling pathway through preventing the heterodimer
formation between H1R and GHSR1a, then leading to upregulation of transcription factors for
NPY expression.
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Olanzapine analogue (E-Olan) with lower affinity to H1R presented negligible enhancement
of pCREB within the nucleus of NPY neurons.
Previously, we have developed an olanzapine analogue (E-Olan) with reduced H1R binding
affinity [29]， which does not increase body weight and food intake in rats [30]. Here, we
examined the E-Olan on the NPY transcription factor pCREB in hypothalamic NPY neurons using
immunocytochemistry. E-Olan did not increased pCREB concentrations in the nucleus of NPY
neurons compared with olanzapine dosing (p<0.01) (Fig 5A and 5B). FMPH significantly
decreased the pCREB compared with the control group and blocked olanzapine increasing pCREB
suggesting olanzapine’s H1R antagonist effect is important for activation of pCREB. Since many
of centrally-NPY release neurons are GABAergic [31; 32; 33], we performed double labeling
GAD65 with pCREB in NPY neurons (Fig 5A). We found that pCREB and GAD65 co-localized
in the hypothalamic NPY neurons, suggesting the olanzapine activated pCREB in GABA
interneurons in hypothalamus.
H1R agonist FMPH suppressed olanzapine induced excessive food intake.
Olanzapine treated rats significantly increased the food intake for the first 4 hours and 16 hours
compared with control rats after icv injection of saline (p<0.001, Fig 7). Both FMPH icv injection
at 100 and 200nmol inhibited the olanzapine-elevated food intake for 4 and 16 hours compared
with olanzapine group with vehicle icv injection (p<0.05, Fig 7). FMPH icv injection did not
significantly alter food intake of rats without olanzapine treatment. These results confirmed that
the H1R antagonism of olanzapine caused increased food intake.
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Discussion
In this study, we found that olanzapine: 1) increased NPY concentrations in hypothalamic neurons,
which were prevented by H1R agonist (FMPH), 2) did not increase hypothalamic NPY of H1R
knockout mice; 3) inhibited the interaction of H1R to GHSR1a, 4) increased the signaling molecule
expression downstream of GHSR1a via antagonising H1R. Furthermore, the olanzapine analogue
(E-Olan) with reduced H1R binding affinity had negligible effect on NPY transcription factor
pCREB of hypothalamic NPY neurons. Finally olanzapine induced excessive food intake was
inhibited by H1R agonist FMPH in rats. These findings suggest that the H1R antagonist property
of olanzapine is important to reduce the interaction of H1R to GHSR1a, which contributed to an
increased NPY via activation of GHSR1a downstream signaling pAMPK-UCP2-FOXO1-pCREB
in hypothalamic neurons. This is an important mechanism of olanzapine induced hyperphagia.

Accumulating data have demonstrated that the incidence of obesity and metabolic disorders in
schizophrenic patients is associated with antipsychotic agents with high affinity for the H1R
including olanzapine, clozapine and risperidone [34; 35; 36], suggesting the role of H1R in
antipsychotic drug-induced obesity. Our previous studies have found that olanzapine increased
body weight gain and hyperphagia via increasing orexigenic NPY level in the hypothalamus [23;
37]. This study showed that olanzapine could directly regulate NPY expression presenting an
inverted U-shape dose-response effect. H1R antagonist PYR increased NPY level similar to with
olanzapine, while H1R agonist FMPH inhibited NPY level in the hypothalamic neurons.
Furthermore, olanzapine fail to increase NPY in the hypothalamic neurons of H1R knockout mice.
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Therefore, it is the H1R antagonistic property of olanzapine that caused an increase of orexigenic
NPY in the hypothalamic neurons.

It is known that GHSR1a has an unusually high level of constitutive activity, i.e.: it can be active
in the absence of a natural ligand ghrelin [38]. GHSR1a is expressed in the NPY neurons and
regulates the NPY expression. Recent data indicate that GHSR1a creates a dimer with several Gprotein coupled receptors involved in appetite control and reward [39; 40]. The present work
represents the first evidence of direct interaction of H1R and GHSR1a in hypothalamic neurons.
We found that H1R co-localises with GHSR1a in the hypothalamic NPY neurons, forming a
heterodimer detected by confocal FRET. The heterodimerization may serve as an allosteric
mechanism to modulate specific GHS-R1a signaling pathways and receptor functionalities,
independently of ghrelin binding to GHSR1a. Furthermore, the interaction between H1R to
GHSR1a was increased by H1R agonist (FMPH) but reduced by H1R antagonist (PYR) in NPY
neurons treated with olanzapine. Olanzapine inhibited FMPH-induced interaction between H1R to
GHSR1a in NPY neurons, suggesting that olanzapine’s H1R antagonism inhibits the interaction
of H1R to GHSR1a in the hypothalamus.
GHSR1a increases NPY, stimulates appetite, and weight gain via the AMPK- FOXO1-pCREB
signalling pathway [12; 27; 41; 42; 43]. We previously found that olanzapine increased GHSR1a
signalling and NPY in the rat hypothalamus [23]. Here, we found that FMPH prevent olanzapine
induced upregulation of GHSR1a signalling AMPK- FOXO1-pCREB in hypothalamic NPY
neurons. The pCREB is a transcription factor of NPY. We showed that olanzapine activated
pCREB in hypothalamic NPY neurons. FMPH blocked elevation of pCREB induced by olanzapine,
which suggested that olanzapine’s H1R antagonist effect is important for activation of pCREB as
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a transcription factor for NPY. We have further demonstrated that these NPY neurons express
GABA, indicating they are hypothalamic interneurons. Our previous study shows when H1R
antagonist property is reduced, E-Olan no longer induces weight gain in rats [29]. The present
study found that olanzapine analogue, E-Olan, with lower affinity to H1R did not activate the NPY
transcription factor pCREB in the hypothalamic neurons.
In summary, we have demonstrated that H1R creates a dimer with GHSR1a in the hypothalamic
NPY neurons. The mechanism is that H1R antagonism of olanzapine disrupted the inhibition effect
of H1R on GHSR1a; therefore increasing AMPK-FOXO1-pCREB signalling by which it
increased NPY concentrations in the hypothalamic neurons leading positive energy balance
regulation. The new compound we have developed by removing H1R antagonism of olanzapine
may provide a better treatment for schizophrenia due to a reduced side-effect of metabolic disorder;
however, further study is required prior to human clinical trial.

Method
Reagents and drugs: Antibodies used in this study were as follows: For immunocytochemistry
first antibodies: goat GHSR1a, mouse H1R, rabbit NPY (all from Santa Cruz Biotechnologies;
dilution factor 1:250), Mouse GAD-65 (Chemicon 1:250); Secondary antibodies: Donkey antigoat-Alexa Fluor 488, Donkey anti-rabbit-Alexa Fluor 488, Donkey-anti-mouse-Alexa Fluor 555,
Donkey-anti-goat-Alexa Fluor 647, Donkey-anti-rabbit-Alexa Fluor 568 all from pCREB (Santa
Cruz Biotechnologies; dilution factor 1:250 IF, 1:1000 WB), pAMPK, AMPK, FOXO1 (Cell
Signaling Technology 1:1000), UCP2 (Santa Cruz Biotechnologies; dilution factor 1:1000 ).
Secondary antibodies for WB were anti-rabbit (for AMPK, pAMPK, FOXO1 and pCREB) or anti-
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goat (for UCP-2) IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnologies, USA;
dilution factor 1:5000). 2-(3-trifluoromethylphenyl) histamine (FMPH), Pyrilamine (PYR) and
Olanzapine were obtained from Sigma-Aldrich (Sigma, NSW, Australia).

Animals and Neuronal cultures: Mouse hypothalamic cell line (mHypoA-59, NPY-GFP neurons,
from CELLutions) grown in monolayer in Dulbecco’s modifed Eagle mediμM (DMEM) (Sigma
D5796, Castle Hill, NSW) with 10% fetal bovine serμM (FBS) (SAFC Biosciences Inc, Lenexa,
KS) and 1% penicillin/streptomycin. They were maintained at 37 °C with 5% CO2. Primary
hypothalamus neurons were from hypothalamic tissues of postnatal day 0 (PN0) of wild type-mice
or CRISPR/Cas9-mediated gene knockout mice. H1R genotype was identified by Gene
Sequencing. Primary hypothalamic cell cultures were prepared based on previous literature [44].
The culture condition was adapted according to Johns Hopkins online protocol [45] with the
culture medium generally consisting of a NeuroBasal medium with an additive B27 and extra
glucose and glutamine. Mouse hypothalamic cell line (mHypoA-59, NPY-GFP neurons, from
CELLutions) grown in monolayer in Dulbecco’s modified Eagle medium (DMEM) (Sigma D5796,
Castle Hill, NSW) with 10% foetal bovine serum (FBS) (SAFC Biosciences Inc, Lenexa, KS) and
1% penicillin/streptomycin. Cells for NPY production assay by flextation were cultured in 96-well
microtiter plates; Cells for Immunofluorescence were plated into polyD-lysine (P6407, SigmaAldrich) coated coverslips in a 24-well plate and maintained at 37°C with 5% CO2; Cells for
Western blot were cultured in 6-well plates. The procedures on animals for primary hypothalamic
neurons were approved by the Animal Ethics Committee, University of Wollongong, NSW,
Australia, and carried out in accordance with the Australian Code of Practice for the Care and Use
of Animals for Scientific Purposes.
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The Detection of NPY Production by flextation: NPY-GFP neurons were seeded at a density of
1.0 × 105 cells/mL and maintained for 24 hours cultivation. Olanzapine, PYR and FMPH with
concentration gradient (for olanzapine: 1-100 μM; for FMPH0.5-10 μM; for PYR 0.5-50 μM) was
applied to the neuron independently for prolonged 3 hours culture. NPY production was
represented by NPY-bound GFP immunoactivity read by the Flexstation 3 multiplate fluorometer
(Molecular Devices Corporation, Sunnyvale, CA). Wavelength of detection was set from 488 nm
to 510 nm, cutoff at 495 nm.

Immunofluorescence and image analysis: For immunochemical staining, neurons cultured on
coverslips were fixed with 4% paraformaldehyde in Dulbecco's PBS for 20 min at room
temperature. The samples were further incubated with 100% methanol for 10 min in -20°C, and
blocked with 5% donkey serum in PBST for 1 hour at room temperature. Then, for the colocalization of H1R and GHSR1a in NPY-GFP neurons, primary antibodies against H1R (rabbit)
and GHSR1a (goat) were applied and incubated for 24 h at 4°C. Species-specific secondary
antibodies conjugated with Alexa Fluor 568 and 647 were applied for further 2 hours incubate at
room temperature. The slips were taken out and sealed on slides in dark for confocal examination.
Same procedures were conducted to prepare primary hypothalamus neurons, anti-NPY (rabbit)
anti-H1R (mouse) anti-GHSR1a (goat) were used as primary antibodies, secondary antibodies
conjugated with Alexa Fluor 488, 568 and 647 were used to visualize NPY, H1R and GHSR1a
respectively. Primary antibodies to pCREB (rabbit), GAD65 (mouse) and species-specific
secondary antibodies conjugated with Alexa Fluor 488 and 555 were used to measure the
expression of pCREB in nucleus of NPY neurons. For the test of NPY and H1R in hypothalamus
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arcuate neurons of wildtype mice, as well as of H1R knock-out mice, the antibodies were antiNPY (rabbit) anti-H1R (mouse) and conjugated with Alexa Fluor 488 (NPY) 555 (H1R). The
slides were observed under confocal microscope (Leica-TCS-SP5 Advanced System, Leica
Microsystem) and obtained images of target receptors individually. The immunoreactivity of
pCREB H1R and NPY in related neurons were quantified by Software Image J.
(http://rsbweb.nih.gov/ij/download.html) from 20 neurons collected from 3 independent culture
wells. Each experiment was repeated 3 times.

Confocal Microscopy FRET and Data Processing: Paraformaldehyde-fixed NPY neurons in 24wells plates coated with coverslips were incubated for 24 h at 4°C with primary antibodies highly
specific to H1R and GHSR1a receptors then the specie-specific secondary antibodies conjugated
to Alexa Fluor 568 and Alexa Fluor 647 dyes, respectively. Anti-H1R-Alexa Fluor 568 was used
as a donor dipole, while anti-GHSR1a-Alexa Fluor 647 was used as acceptor dipole. The images
were obtained by Olympus Fluoview FV 1000 laser scanning confocal microscope with 63/1.4
NA objective. The donor was excited with a krypton laser at 561 nm, while the acceptor was
excited with an argon laser at 633 nm. The emissions were collected with 620/40nm and 680/30nm
LP filter.

Primary hypothalamus neurons were paraformaldehyde-fixed and incubated with primary
antibodies to GHSR1a and H1R receptors then dyed by specie-specific secondary antibodies
conjugated to Alexa Fluor 488 and 568 individually. Anti-GHSR1a-Alexa Fluor 488 was used as
a donor dipole, while anti-H1R-Alexa Fluor 568 was used as acceptor dipole. The donor was
excited with a krypton laser at 488 nm, while the acceptor was excited with an argon laser at 561
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nm. The emissions were collected with 530/30 and 620/40nm LP filter. 20 images were acquired
for each FRET analysis according to referred algorithm [46; 47]. FRET efficiencies (E) for the
sensitized emission were calculated and analyzed using FRET-SE Wizard Software (Leica
Microsystems Pty Ltd, NSW Australia). The distance (r) between the donor and the acceptor was
calculated by selecting small regions of interest (ROI) using the equation r=R0 [(1/E)-1]1/6. R0 is
the Förster’s distance. The FRET efficiencies directly indicate the distance between donor and
acceptor [48].

Western blot: NPY-GFP neurons cultured in 6-wells plates and treated by olanzapine and the
combination of olanzapine and FMPH. Cells were harvested using lysis buffer (containing NP40,
Protease Inhibitor Cocktail, 1 mM PMSF and 0.5 mM β-glycerophosphate). The protein
concentrations were determined by DCTM Protein Assay kit (5000121, Bio-Rad, USA) and
detected through a SpectraMax Plus384 absorbance microplate reader (Molecular Devices, USA).
10µg proteins of each sample were heated in Laemmli buffer at 95 °C before loaded to 8% SDSPAGE gels for fractionation, followed by Electrophoresis under 120 V for 1.5 hours. Then the
proteins were transferred onto Immun-BlotTM PVDF membranes (Bio-Rad, USA). After blocked
in 5% BSA (diluted in TBST), the membranes were incubated with pCREB antibody (Santa Cruz
Biotechnologies; dilution factor 1:1000) and pAMPK, AMPK, UCP2 and FOXO1 antibodies (Cell
Signalling Technology; dilution factor 1:1000) separately in TBST containing 1% BSA overnight
at 4°C. Secondary antibodies were anti-rabbit IgG conjugated with horseradish peroxidase for
pAMPK, AMPK, FOXO1 and pCREB (Santa Cruz, CA; dilution factor 1:5000). Secondary
antibody against UCP2 was goat IgG conjugated with horseradish peroxidase (Santa Cruz, CA;
dilution factor 1:5000). For visualization, ECL detection reagents were used and films were
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exposed on the AGFA CP1000 Tabletop Processor (AGFA Healthcarem Scoresby, VIC). Films
were analyzed using Quantity One software connected to a GS-690 Imaging Densitometer (BioRad, Hercules, and CA).
FMPH intervention: To further investigate H1 antagonism of olanzapine induced food intake, an
H1 receptor agonist, FMPH was injected in olanzapine treated rats. Briefly, a 24-gauge guide
cannula was implanted with into the lateral ventricle of SD rat (1.0 mm posterior to the bregma,
1.5 mm lateral to the midline, and 3.5 mm below the top skull) [49]. After 1 week, the rats were
given olanzapine or vehicle for 4 days. A cookie dough pellet (62% carbohydrate, 22% protein, 6%
fiber, and 10% vitamins and minerals) mixed with either olanzapine (1 mg/kg) or placebo 3 times
daily at 8-hour intervals at 7 am, 3 pm, and 11 pm [50]. On day 5, two dosage of H1 receptor
agonist, FMPH, (100 or 200 nmol) or saline as a control were injected into lateral ventricle of rats
(in 5 μL, at a rate of 5μL/min). Thirty minutes later, the rats were given olanzapine or vehicle in
cookie dough pellet. We measured the food intake of the rats at 4 and 16 hours after the olanzapine
or vehicle were administered.

Statistical analysis: SPSS (version 21; Chicago, IL) was used for statistical analysis. One-way
analysis of variance (ANOVA) with post-hoc Tukey’s tests was performed for multiple
comparisons. Data were expressed as mean± SEM, and p< 0.05 was considered statistically
significant.

Figure Legends
Fig 1. A: Olanzapine (Ola) stimulated neuropeptide immune-reactivity (NPY-IR) in a dose
response manner in hypothalamic NPY-GFP neurons in 3 hours. B: H1R agonist 2-(316

trifluoromethylphenyl) histamine dihydrogenmaleate (FMPH) inhibited NPY-IR in 3 hours. C:
H1R antagonist pyrilamine (PYR) stimulated NPY-IR in a pattern similar to olanzapine in 3 hours.
* p<0.05 vs. nil control; **: p<0.01 vs. nil control.
Fig 2. Fluorescence immune-reactivity of neuropeptide Y (NPY) and histamine 1 receptor (H1R)
in cultured hypothalamic neurons. A: The NPY neurons (Green) of the hypothalamic arcuate
nucleus express H1R (red) and co-localised (Merge). B: Olanzapine (Ola, 25μM) increases NPY
expression in wildtype, but not H1R-KO mice. **p<0.01 and *** p<0.001.
Fig 3. Triple immunofluorescence labelling showing co-localisation of NPY, H1R, and GHSR1a
in the neuron of hypothalamic arcuate nucleus using primary cell culture (Row A). Row-B shows
that GHSR1a and H1R are co-localised (Merge) form heterodimer (FRET, purple). Row-C
indicates that GHSR1a does not show FRET without adding H1R antibody (no fluorescence donor).
Row-D indicates that H1R does not show FRET without adding GHSR1a antibody (no
fluorescence acceptor). The FRET was increased by H1R antagonist FMPH, but decreased by Olan
and H1R agonist in soma and dendrites (E and F) of primary hypothalamic neurons. *p<0.05 vs.
control (CON), **p<0.01 vs. CON and ##p<0.01 vs. FMPH.
Fig 4. Fluorescence immunoreactivity of NPY-GFP neurons express H1R and GHSR1a, which
are FRET positive. Row-A shows co-localization of NPY, H1R and GHSR1a (Merge). Row-B
shows that FRET is positive (purple) indicating H1R and GHSR1a interaction. C shows that H1R
antagonist FMPH increased FRET but olanzapine (OLA) prevented FRET induced by OLA.
**p<0.01 vs. control, ##p<0.01 vs. FMPH.
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Fig 5. The expression of pAMPKα-FOXO1-pCREB signaling in response to olanzapine (OLA)
and H1R agonist FMPH. OLA increases pAMPKα, FOXO1, and pCREB which can be prevented
by FMPH in hypothalamic NPY-GFP neurons. *p<0.05 vs CON, #p<0.05 vs Olan.
Fig 6. The pCREB immunoreactivity in the nucleus of hypothalamic NPY-GFP neurons is
regulated by H1R activity. The first row shows that pCREB was stimulated by olanzapine (Ola),
but not olanzapine with reduced H1R activity (OlzEt). H1R agonist FMPH reduced pCREB which
was reversed by Ola. The second row showed these neurons are GAD65 positive which was not
affected by any treatment used here. The third row showed double labelling of pCREB and GAD65.
B shows the quantitative data of A (n= 20), *p<0.05, **p<0.01 vs. control. The NPY transcription
factor pCREB is positive in GAD65, suggesting these neurons are hypothalamic interneurons.
Fig 7. H1R agonist FMPH administered into intracerebral ventricle inhibiting olanzapine (OLA)induced excessive food intake for 4 and 16 hours. All data were presented as mean ± SEM. *:
p<0.05, **: p<0.01, ***: p<0.001 vs. Ola. FMPH1: 100 nmol, FMPH2: 200 nmol FMPH (n =5 –
8 mice per group).
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